A team of researchers in Kansai is set to begin clinical trials next month to develop medicine to help grow teeth.

The researchers, including from Kitano Hospital and Kyoto University Hospital, will conduct trials for teething medicine, aimed at treating people with congenital anodontia who are born with few teeth.

To check its safety, the experimental drug will first be administered to adult men who have lost back teeth, before it is tested on children with congenital anodontia. The team aims to put the treatment into practical use in around 2030.

  • Beaver@lemmy.ca
    link
    fedilink
    English
    arrow-up
    41
    arrow-down
    2
    ·
    3 months ago

    One of the most exciting developments in recent times

    • ColeSloth@discuss.tchncs.de
      link
      fedilink
      English
      arrow-up
      3
      arrow-down
      14
      ·
      edit-2
      3 months ago

      Not actually. This doesn’t do anything for most normal people. It’s for people who didn’t properly have a normal 2nd set of teeth. So if you just had your “adult” set of teeth go bad, this won’t help you.

      *After doing a little more research, my above statement is correct. This drug only inhibits the protein that people with congenital anodontia have, so those people are able to start growing teeth. Less than 1% of people have congenital anodontia.

      The little mention in the article about it leading to growing teeth in people who have lost them due to cavities (as the person with all the upvotes that replied to me here) is complete hyperbole in the article. This protein suppression medication can’t work on someone with a normal protein. It was just mentioned as fluff to get more press about “future possibilities”.

      • Hobthrob@lemmy.world
        link
        fedilink
        English
        arrow-up
        27
        arrow-down
        1
        ·
        3 months ago

        The article says that they hope to regrow teeth for people who have lost their teeth to cavities, and the initial test is being done on adults who have lost back teeth. So pretty much the exact target audience you say it wouldn’t target.

        • AwesomeLowlander
          link
          fedilink
          English
          arrow-up
          2
          ·
          3 months ago

          It’s really weird though. Why specify that you’re targeting specifically kids with a disorder when your treatment is being tested on adults, and would work on any adult who has lost teeth for any reason?

          • ColeSloth@discuss.tchncs.de
            link
            fedilink
            English
            arrow-up
            1
            ·
            3 months ago

            Because /hobthrob is incorrect. This medication will not and cannot be used to regrow teeth in people that don’t have the genetic disorder “congenital anodontia”. The drug can only help that >1% with the disorder.

          • AliasAKA@lemmy.world
            link
            fedilink
            English
            arrow-up
            1
            ·
            3 months ago

            Speculating, but probably because kids without any teeth and a genetic basis of that disease would pay for this treatment out of medical coverage, not dental coverage, at least in the US, and getting it approved for specifically that indication is easier, faster, and likely higher profit than the admittedly larger population but smaller insured availability of funds that would be the dental market.

            Markets shouldn’t drive drug research, public health benefit should, but shrugs

            • AwesomeLowlander
              link
              fedilink
              English
              arrow-up
              2
              ·
              3 months ago

              Good thought, but it looks like they’re a Japanese team conducting trials in Japan, so the US excuse for an insurance system shouldn’t be a factor? IDK

              • AliasAKA@lemmy.world
                link
                fedilink
                English
                arrow-up
                2
                ·
                3 months ago

                Quick search tells me that they have a national dental plan that covers 70%, but has limits on which procedures materials etc are covered. In other words, they may not cover this procedure if it’s more expensive than a traditional implant.

                Additionally, there’s harmonization efforts between Japan and the US FDA; if fully expect they’re running clinical trials in JP with hopes for a later release abroad, and the US is a huge market so they’d still be angling that I’d think.

        • ColeSloth@discuss.tchncs.de
          link
          fedilink
          English
          arrow-up
          2
          arrow-down
          2
          ·
          edit-2
          3 months ago

          My bad. I guess this is a completely different thing from one I read about around 6 months ago, then.

          *Nevermind. This is the same thing and everyone else in here is mistaken. Go read any other articles about this. The medication suppresses a protein that people with congenital anodontia have, and that is what makes them start growing teeth. Normal people do not have that protein issue, so the drug can’t help.

          • AwesomeLowlander
            link
            fedilink
            English
            arrow-up
            3
            ·
            3 months ago

            Given the average quality of science reporting and the lack of actual journal articles, it might be the same thing with a misunderstanding in either the earlier article or this one.

            • orrk@lemmy.world
              link
              fedilink
              English
              arrow-up
              2
              ·
              3 months ago

              science reporting is awesome, I love when people start pushing random BS because they decided they needed to “dumb it down” because they themselves were too dumb to get it in the first place

              • ColeSloth@discuss.tchncs.de
                link
                fedilink
                English
                arrow-up
                1
                ·
                3 months ago

                Well that’s what happened with this article. Their little mention of growing teeth lost from cavities is complete hyperbole. This treatment suppresses a protein found in the less than 1% of people who have congenital anodontia. It can’t be used at all to help grow teeth for anyone else.

            • ColeSloth@discuss.tchncs.de
              link
              fedilink
              English
              arrow-up
              1
              arrow-down
              1
              ·
              3 months ago

              Oh man. It seems the only misunderstanding is that no one else in here understands the article or what congenital anodontia actually is. So what I had initially stated, and per this article, it won’t help 99% of people.

              • AwesomeLowlander
                link
                fedilink
                English
                arrow-up
                1
                ·
                3 months ago

                The treatment may be applied in the future to people who have permanently lost teeth due to cavities and other problems.

                How do we not understand the article? If the article is full of bull, that’s another story

                • ColeSloth@discuss.tchncs.de
                  link
                  fedilink
                  English
                  arrow-up
                  1
                  ·
                  3 months ago

                  The context and explanation of everything else in the article in everything but that one cavity paragraph explains what it can treat and how it does it. Then that one paragraph says it may be used. In full context of the entire article (which is trash) it can be interpreted as not really for cavity missing teeth.